Coeptis Therapeutics Holdings, Inc.
COEP
$15.92
-$0.04-0.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 69.63% | 89.80% | 97.22% | -25.41% | -58.11% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.74% | 66.96% | 40.98% | -35.76% | -72.89% |
| Operating Income | -15.65% | -59.87% | -38.82% | 35.76% | 72.89% |
| Income Before Tax | -58.50% | -42.81% | -13.98% | 19.81% | 71.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.50% | -42.81% | -13.98% | 19.81% | 71.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 65.52% | -- | -- | -- | -- |
| Net Income | -58.11% | -49.64% | -1.88% | 48.13% | 72.72% |
| EBIT | -15.65% | -59.87% | -38.82% | 35.76% | 72.89% |
| EBITDA | -15.34% | -63.93% | -40.77% | 38.63% | 75.28% |
| EPS Basic | -1,227.13% | 24.54% | 41.08% | 57.18% | 99.09% |
| Normalized Basic EPS | -963.42% | 15.98% | 45.28% | 75.61% | 99.14% |
| EPS Diluted | -1,227.13% | 24.54% | 41.08% | 57.18% | 99.09% |
| Normalized Diluted EPS | -963.42% | 15.98% | 45.28% | 75.61% | 99.14% |
| Average Basic Shares Outstanding | -88.08% | 98.31% | 72.92% | 21.13% | 2,887.35% |
| Average Diluted Shares Outstanding | -88.08% | 98.31% | 72.92% | 21.13% | 2,887.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |